Prothena Reports Results From the Phase 3 VITAL Amyloidosis Study of NEOD001 (Birtamimab) in AL Amyloidosis | oneAMYLOIDOSISvoice

Prothena Reports Results From the Phase 3 VITAL Amyloidosis Study of NEOD001 (Birtamimab) in AL Amyloidosis


Prothena Corporation PLC, a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amyloidosis study of NEOD001 (birtamimab) in newly diagnosed, treatment naive patients with AL amyloidosis and cardiac dysfunction (N=260), which was discontinued in 2018. The final hazard ratio (HR) for the composite primary endpoint (time to all-cause mortality or time to cardiac hospitalization more than 90 days after first infusion of study drug) of 0.835 (95% CI: 0.5799, 1.2011; p=0.3300) was consistent with the futility analysis reported in April 2018.
 
Post hoc analyses of all-cause mortality revealed a potential survival benefit favoring NEOD001 in the category of patients at highest risk for early mortality (Mayo Stage IV, n=77) with a HR of 0.544 (95% CI: 0.2738, 1.0826; p=0.0787). This potential survival benefit was more pronounced in Mayo Stage IV patients during the initial 12 months of treatment, with a HR of 0.498 (95% CI: 0.2404, 1.0304; p=0.0556).
 
Prothena Reports Results From The Phase 3 VITAL Amyloidosis Study Of NEOD001 (Birtamimab) In AL Amyloidosis

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close